Last reviewed · How we verify
NCT05761457
Efficacy and Safety of Autologous Cryopreserved Platelets in Patients With PTR
NA trial testing Cryopreserved autologous platelet transfusion in Platelet Transfusion Refractoriness in 25 participants. Status unknown.
10 January 2025
Quick facts
| Lead sponsor | The First Affiliated Hospital of Soochow University |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 25 |
| Start date | 1 March 2023 |
| Primary completion | 10 January 2025 |
| Estimated completion | 10 January 2025 |
| Sites | 1 location across China |
Drugs / interventions tested
- Cryopreserved autologous platelet transfusion
Conditions studied
- Platelet Transfusion Refractoriness — all drugs for Platelet Transfusion Refractoriness →
Sponsor
The First Affiliated Hospital of Soochow University
Who can join
Adults 15 to 70, any sex, with Platelet Transfusion Refractoriness. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to improve the platelet level of PTR patients; Prevent and improve bleeding; Help patients to successfully through the bone marrow suppression period after chemotherapy; Reduce the overall rate of PTR and allo-immunity; Saving platelet resources and reducing blood burden.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05761457
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Platelet Transfusion Refractoriness
Currently open trials in the same condition.
- NCT06792019 — Study of CM313(SC) Injection in Subjects With Platelet Transfusion Refractoriness · Phase 1, PHASE2 · recruiting
- NCT06254560 — Rituximab for Serious Aplastic Anemia With Platelet Transfusion Refractoriness · Phase 2 · recruiting
Other The First Affiliated Hospital of Soochow University trials
Trials by the same sponsor.
- NCT07350863 — U69-CART-Cells For R/R T-ALL · Phase 1 · recruiting
- NCT06985498 — Immunotherapy Combined With Auto-HSCT and CD22/CD19 CAR-T Sandwich Strategy for B-ALL · Phase 2 · not yet recruiting
- NCT07463651 — MRD-guided Maintenance Post-HCT: Gilteritini vs Sorafenib · Phase 3 · recruiting
- NCT07500753 — A Single-arm, Prospective Study of a Clad-LABU Conditioning Regimen in HSCT for R/R MDS/AML in Elderly Patients · NA · recruiting
- NCT07511426 — U96-CAR-T-Cells For R/R B-ALL · Phase 1 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05761457 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by The First Affiliated Hospital of Soochow University
- Last refreshed: 9 March 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05761457.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing